Table 2 Ten-year net survival and 5-year conditional net survival of 5-year survivors.

All patients

AML

38.8

(37.9–39.7)

90.3

(89.2–91.5)

ALL

45.2

(44.0–46.4)

91.7

(90.5–93.0)

MDS

44.2

(42.3–46.1)

89.5

(87.0–91.9)

ML

40.5

(38.8–42.3)

94.0

(92.0–95.9)

AA

78.1

(76.2–80.1)

97.9

(96.8–99.0)

CML

55.5

(53.7–57.4)

94.6

(93.2–95.9)

MM/PCD

21.1

(15.6–26.6)

77.9

(65.5–90.3)

ATL

27.6

(24.9–30.3)

87.8

(82.1–93.4)

Younger adults

AML

39.6

(38.5–40.7)

89.3

(87.8–90.7)

ALL

42.4

(40.9–43.9)

89.2

(87.3–91.1)

MDS

46.6

(44.4–48.8)

89.7

(87.1–92.3)

ML

40.8

(38.9–42.8)

93.4

(91.1–95.6)

AA

72.7

(70.0–75.5)

97.2

(95.4–98.9)

CML

55.2

(53.3–57.2)

94.3

(92.8–95.8)

MM/PCD

21.4

(15.5–27.3)

76.6

(63.4–89.8)

ATL

28.9

(25.7–32.0)

88.1

(82.2–94.1)

Children

AML

53.2

(50.7–55.8)

96.1

(94.5–97.7)

ALL

52.6

(50.6–54.7)

95.0

(93.5–96.5)

MDS

66.8

(61.2–72.3)

96.3

(92.5–100.0)

ML

52.8

(47.0–58.6)

98.0

(95.1–100.9)

AA

89.3

(87.0–91.7)

99.0

(97.9–100.1)

Older adults

AML

22.3

(18.9–25.8)

79.6

(69.0–90.2)

ALL

29.6

(19.3–39.9)

89.2

(61.0–117.5)

MDS

23.9

(18.0–29.9)

71.8

(56.2–87.3)

ML

31.1

(25.4–36.7)

93.3

(81.6–105.0)

ATL

24.0

(17.9–30.1)

84.2

(67.4–101.0)